NO20032542L - Dempede anti-CD28-antistoffer og anvendelse derav - Google Patents

Dempede anti-CD28-antistoffer og anvendelse derav

Info

Publication number
NO20032542L
NO20032542L NO20032542A NO20032542A NO20032542L NO 20032542 L NO20032542 L NO 20032542L NO 20032542 A NO20032542 A NO 20032542A NO 20032542 A NO20032542 A NO 20032542A NO 20032542 L NO20032542 L NO 20032542L
Authority
NO
Norway
Prior art keywords
antibodies
attenuated anti
attenuated
Prior art date
Application number
NO20032542A
Other languages
English (en)
Other versions
NO20032542D0 (no
Inventor
J Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20032542D0 publication Critical patent/NO20032542D0/no
Publication of NO20032542L publication Critical patent/NO20032542L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20032542A 2000-12-14 2003-06-05 Dempede anti-CD28-antistoffer og anvendelse derav NO20032542L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number Publication Date
NO20032542D0 NO20032542D0 (no) 2003-06-05
NO20032542L true NO20032542L (no) 2003-08-07

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032542A NO20032542L (no) 2000-12-14 2003-06-05 Dempede anti-CD28-antistoffer og anvendelse derav

Country Status (18)

Country Link
EP (1) EP1341553A4 (no)
JP (1) JP2004515243A (no)
KR (1) KR20040020866A (no)
CN (1) CN1272345C (no)
AR (1) AR031924A1 (no)
AU (2) AU2608602A (no)
BR (1) BR0116686A (no)
CA (1) CA2432736A1 (no)
CZ (1) CZ20031909A3 (no)
HU (1) HUP0400697A3 (no)
IL (1) IL156262A0 (no)
MX (1) MXPA03005327A (no)
NO (1) NO20032542L (no)
NZ (1) NZ526569A (no)
PL (1) PL363239A1 (no)
RU (1) RU2261723C2 (no)
WO (1) WO2002047721A1 (no)
ZA (1) ZA200305384B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113692286A (zh) * 2019-03-14 2021-11-23 比昂生物制剂公司 一种用于免疫抑制的方法
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US12612459B2 (en) 2019-12-02 2026-04-28 Biond Biologics Ltd. Methods of identifying agents that block MCD28 cleavage by MMPS
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
JP2026502759A (ja) * 2023-01-06 2026-01-27 アイジーエム バイオサイエンシズ インコーポレイテッド Ｔ細胞共刺激多量体結合分子及びその使用
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28

Also Published As

Publication number Publication date
CZ20031909A3 (cs) 2003-11-12
CA2432736A1 (en) 2002-06-20
ZA200305384B (en) 2004-10-11
IL156262A0 (en) 2004-01-04
JP2004515243A (ja) 2004-05-27
KR20040020866A (ko) 2004-03-09
EP1341553A1 (en) 2003-09-10
RU2003121231A (ru) 2005-02-10
AR031924A1 (es) 2003-10-08
NZ526569A (en) 2005-07-29
AU2002226086C1 (en) 2006-03-09
CN1272345C (zh) 2006-08-30
EP1341553A4 (en) 2004-07-28
PL363239A1 (en) 2004-11-15
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
AU2608602A (en) 2002-06-24
BR0116686A (pt) 2003-12-30
AU2002226086B2 (en) 2005-08-25
CN1489473A (zh) 2004-04-14
RU2261723C2 (ru) 2005-10-10
NO20032542D0 (no) 2003-06-05
MXPA03005327A (es) 2004-12-03
HUP0400697A3 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
NO20032542D0 (no) Dempede anti-CD28-antistoffer og anvendelse derav
CY2019029I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20033418L (no) Immunregulatoriske antistoffer og anvendelse derav
NO20030614L (no) Anti-IL-12-antistoffer, sammensetninger, fremgangsmåter og anvendelser
IS7041A (is) 5-HT viðtakabindlar og notkun þeirra
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
TWI316088B (en) Anti-tnf alpha antibodies and their uses
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
IS6411A (is) Kaspasa tálmar og notkun þeirra
FI20002210L (fi) Rannelaite
NO20033456L (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
DK1278763T3 (da) 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
FI20002209L (fi) Rannelaite
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DK1339292T3 (da) Sammensætning og fremgangsmåde
DK1322597T3 (da) Fremgangsmåde og intermediære
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application